DUBLIN--(BUSINESS WIRE)--Aug 23, 2018--The "Liquid Biopsy Market, Global Analysis by Cancer, Product, Circulating Biomarkers, Clinical Application, Regions, and Companies" report has been added to ResearchAndMarkets.com's offering.

Liquid Biopsy Market is projected to exceed US$ 3.4 Billion by the year 2024, witnessing the worldwide increasing prevalence of cancer and raising awareness regarding the minimal invasive liquid biopsy technology across the world.

Today, liquid biopsy has paved the road of cancer diagnosis and treatment by offering a complete treatment response in real time without the need of serial traditional (solid-tissue) biopsies.

Today, the population across the globe is growing and aging and so is the global burden of cancer; it is estimated that by the year 2030, the global cancer burden will reach nearly 21.7 Million new cancer cases and be around 13 Million cancer deaths. It is also expected that the low and middle income countries accounts for 60% of the cancer deaths due to the lack of medical resources and proper healthcare systems.

The cases of cancer increases very rapidly around the world owing to the adoption of unhealthy lifestyles and behaviors such as smoking, poor diet, physical inactivity etc. These rising cases of cancer will drive the liquid biopsy market to thrive in the coming years. As liquid biopsy is a simple and non-invasive technique it enables physicians to discover a range of information about patient's tumor and provide clues about the treatment that a patient's needs.

All the 9 Companies Studied in the Report have been Studied from 3 Points

Company Overview Product Portfolio Financial Insight

This market research report provides a complete analysis of the Liquid Biopsy Market, Growth Drivers, Challenges, and their projections for the upcoming years.

By Cancer

Lung Cancer Breast Cancer Colorectal Cancer Prostate Cancer Others

By Product

Kits & Consumables Instruments Services

By Circulating Biomarkers

Circulating Tumor Cells (CTCs) Circulating Tumor DNA (ctDNA) Exosomes

By Sample

Plasma/Serum Urine Others

By Clinical Application

Monitoring Prognosis Theranostics Screening

By Companies

Thermo Fisher Scientific Inc. Roche Diagnostics Bio-Rad Laboratories Inc. Biocept Inc. Biocartis Myriad Genetics, Inc. Genomic Health NeoGenomics Laboratories Qiagen

For more information about this report visit https://www.researchandmarkets.com/research/cdqhv3/3_4_bn_liquid?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180823005412/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Biomarkers

KEYWORD:

INDUSTRY KEYWORD: HEALTH MEDICAL DEVICES ONCOLOGY

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 08/23/2018 08:56 AM/DISC: 08/23/2018 08:56 AM

http://www.businesswire.com/news/home/20180823005412/en